SAN DIEGO – Johnson & Johnson/AbbVie Inc.'s ambitious expansion plans for the blockbuster BTK inhibitor Imbruvica got a leg up with promising updated data from a Phase I/II trial of graft-versus-host disease presented in a late-breaker session at the American Society of Hematology meeting Dec. 5.
After allogenic stem cell and bone marrow transplants, donor cells may attack the body, causing GVHD, which can develop into...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

